Kiora Pharmaceuticals Stock Forward View - Double Exponential Smoothing
| KPRX Stock | USD 2.17 -0.01 -0.46% |
The hype cycle around Kiora Pharmaceuticals can be quantified and compared to historical sentiment baselines. This module uses that comparison to generate price predictions that reflect the sentiment component of market value.
In the current reporting cycle, Kiora Pharmaceuticals posts RSI reading of 52, consistent with balanced price action. Values near 50 generally reflect equilibrium between upward and downward pressure.Momentum
Impartial
Oversold | Overbought |
This view relates Kiora Pharmaceuticals' headline activity to recent price response context.
The Double Exponential Smoothing forecasted value of Kiora Pharmaceuticals on the next trading day is expected to be 2.16 with a mean absolute deviation of 0.05 and the sum of the absolute errors of 2.81.Kiora Pharmaceuticals after-hype prediction price | $ 2.17 |
The sentiment view is a companion to forecasting, technical studies, analyst estimates, and earnings trends.
Cross-verify projections for Kiora Pharmaceuticals using Historical Fundamental Analysis of Kiora Pharmaceuticals. The view supplies historical context for the projection discussion.Our How to Buy Kiora Stock guide explains the steps to invest in Kiora Pharmaceuticals stock.Kiora Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Kiora price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Kiora using various technical indicators. When you analyze Kiora charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Kiora Pharmaceuticals Double Exponential Smoothing Price Forecast For the 12th of March 2026
Given 90 days horizon, the Double Exponential Smoothing forecasted value of Kiora Pharmaceuticals on the next trading day is expected to be 2.16 with a mean absolute deviation of 0.05 , mean absolute percentage error of 0.0035 , and the sum of the absolute errors of 2.81 .Please note that although there have been many attempts to predict Kiora Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Kiora Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Kiora Pharmaceuticals Stock Forecast Pattern
| Backtest Kiora Pharmaceuticals | Kiora Pharmaceuticals Price Prediction | Research Analysis |
Kiora Pharmaceuticals Forecasted Value
This next-day forecast for Kiora Pharmaceuticals uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Kiora Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Kiora Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0107 |
| MAD | Mean absolute deviation | 0.0476 |
| MAPE | Mean absolute percentage error | 0.0224 |
| SAE | Sum of the absolute errors | 2.81 |
Experienced Kiora Pharmaceuticals' investors use mean reversion as a complement to momentum analysis: momentum identifies the trend; mean reversion identifies when that trend has extended beyond sustainable levels.
Kiora Pharmaceuticals After-Hype Price Density Analysis
This probability distribution for Kiora Pharmaceuticals is built from Monte Carlo simulations that incorporate Kiora Pharmaceuticals' historical volatility, mean reversion tendencies, and jump risk. The resulting distribution captures a broader range of Kiora Pharmaceuticals outcomes than simple linear.
Next price density |
| Expected price to next headline |
Kiora Pharmaceuticals Estimiated After-Hype Price Volatility
The boundaries derived from Kiora Pharmaceuticals' historical news analysis represent the range within which Kiora Pharmaceuticals's price has typically settled after comparable headline events. Kiora Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.11 and 4.89, respectively. Outcomes outside these boundaries are less common but not rare for Kiora Pharmaceuticals.
Current Value
The after-hype framework applied to Kiora Pharmaceuticals assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Kiora Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Kiora Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiora Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Kiora Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.06 | 2.72 | 0.00 | 0.00 | 0 Events | 3 Events | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
2.17 | 2.17 | 0.00 |
|
Kiora Pharmaceuticals Hype Timeline
Kiora Pharmaceuticals is now traded for 2.17. The company stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Kiora is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is now at 0.06%. %. The volatility of related hype on Kiora Pharmaceuticals is about 11826.09%, with the expected price after the next announcement by competition of 2.17. About 22.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.35. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kiora Pharmaceuticals recorded a loss per share of 2.19. The company last dividend was issued on the 30th of August 2019. The firm completed a 1:9 stock split on 11th of June 2024. Given the investment horizon of 90 days the next projected press release will be uncertain. Cross-verify projections for Kiora Pharmaceuticals using Historical Fundamental Analysis of Kiora Pharmaceuticals. The view supplies historical context for the projection discussion.Our How to Buy Kiora Stock guide explains the steps to invest in Kiora Pharmaceuticals stock.Kiora Pharmaceuticals Related Hype Analysis
Understanding Kiora Pharmaceuticals' position within its competitive set helps investors assess whether news affecting a peer is a headwind or tailwind for Kiora Pharmaceuticals. This distinction requires knowledge of the competitive dynamics specific to Kiora Pharmaceuticals' industry.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| APRE | Aprea Therapeutics | 0.00 | 0 per month | 0.00 | -0.0032 | 11.29 | -7.46 | 46.26 | |
| BCDA | Biocardia | 0.00 | 0 per month | 0.00 | -0.03 | 5.98 | -6.03 | 20.06 | |
| ACXP | Acurx Pharmaceuticals LLC | -0.10 | 6 per month | 4.29 | 0.11 | 38.01 | -8.54 | 49.19 | |
| INAB | In8bio Inc | 0.14 | 8 per month | 4.76 | 0.07 | 12.90 | -8.33 | 37.96 | |
| CELZ | Creative Medical Technology | 0.00 | 0 per month | 0.00 | -0.02 | 7.17 | -8.89 | 25.03 | |
| APVO | Aptevo Therapeutics | 0.00 | 0 per month | 0.00 | -0.29 | 6.56 | -11.40 | 40.48 | |
| HCWB | HCW Biologics | 0.00 | 0 per month | 0.00 | -0.27 | 8.11 | -11.97 | 42.74 | |
| PHIO | Phio Pharmaceuticals Corp | -0.27 | 11 per month | 5.51 | 0.06 | 13.86 | -9.65 | 56.33 | |
| ADIL | Adial Pharmaceuticals | -0.11 | 8 per month | 0.00 | -0.38 | 6.40 | -9.04 | 34.48 | |
| RNAZ | Transcode Therapeutics | 0.57 | 7 per month | 4.91 | 0.06 | 16.20 | -7.47 | 35.66 |
Other Forecasting Options for Kiora Pharmaceuticals
Understanding Kiora Pharmaceuticals' price movement is a prerequisite for any investor considering Kiora as a position. Kiora Stock price charts are frequently cluttered with noise that can interfere with accurate interpretation.Kiora Pharmaceuticals Related Equities
The following equities are related to Kiora Pharmaceuticals within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Kiora Pharmaceuticals against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Kiora Pharmaceuticals Market Strength Events
For traders and investors in Kiora Pharmaceuticals, market strength indicators offer a quantitative framework for evaluating the stock's responsiveness to market conditions. These tools help identify when trading Kiora Pharmaceuticals shares is most likely to generate favorable returns.
Kiora Pharmaceuticals Risk Indicators
Analyzing Kiora Pharmaceuticals' risk indicators provides a critical input for price forecasting and investment risk management. By quantifying the risk in Kiora Pharmaceuticals' investment, investors can make more informed decisions about their exposure and hedging strategies.
| Mean Deviation | 2.18 | |||
| Semi Deviation | 2.36 | |||
| Standard Deviation | 2.72 | |||
| Variance | 7.4 | |||
| Downside Variance | 6.41 | |||
| Semi Variance | 5.57 | |||
| Expected Short fall | -2.53 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Kiora Pharmaceuticals
Coverage intensity for Kiora Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Kiora Pharmaceuticals Short Properties
Short sentiment tied to Kiora Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 4.1 M | |
| Cash And Short Term Investments | 26.8 M |
More Resources for Kiora Stock Analysis
Reviewing Kiora Pharmaceuticals commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Kiora Stock:Cross-verify projections for Kiora Pharmaceuticals using Historical Fundamental Analysis of Kiora Pharmaceuticals. The view supplies historical context for the projection discussion.Our How to Buy Kiora Stock guide explains the steps to invest in Kiora Pharmaceuticals stock.Analysis related to Kiora Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Understanding Kiora Pharmaceuticals includes distinguishing between market value and book value, where book value reflects Kiora accounting equity. Kiora Pharmaceuticals' market capitalization is 7.87 M. A P/B ratio of 0.35 suggests Kiora Pharmaceuticals trades near or below book value. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
The concept of value for Kiora Pharmaceuticals differs from its quoted price, since each reflects a different lens. For Kiora Pharmaceuticals, key inputs include a P/B ratio of 0.35, ROE of -32.58%, and revenue of 16 M. Trading price represents the transaction level agreed by market participants.